Unihealth Hospitals Limited (NSE: UNIHEALTH) is a Mumbai, Maharashtra-based company in the Hospitals and Healthcare Centers industry. With a market capitalisation of ₹863 Cr, it ranks #1,667 by market cap among the 6,197 Indian listed companies on FinBizNet, and #24 of 46 in Hospitals and Healthcare Centers. At ₹549.95 (as of 16 Nov 2026), the share price is 32.9% below its 52-week high of ₹820.00 and 254.8% above its 52-week low of ₹155.00. The share price is up 242.2% over one year and down 23.9% over three months.
| Current Price | ₹549.95 |
|---|---|
| Market Cap | ₹863 Cr |
| NSE Symbol | UNIHEALTH |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Facilities > Hospitals and Healthcare Centers |
| P/E Ratio | 33.3 |
| Return on Equity | 30.34% |
| Return on Assets | 12.40% |
| 52-Week Range | ₹155.00 – ₹820.00 |
| 1-Year Price Change | +242.2% |
| 3-Month Price Change | -23.9% |
| Beta (1Y) | -0.75 |
| Headquarters | Mumbai, Maharashtra |
| Website | www.unihealthonline.com |
Promoters held 64.82% of Unihealth Hospitals Limited's shares as of Sept 2026, against 69.14% in Sept 2025 (−4.32 percentage points).
Unihealth Hospitals Limited, together with its subsidiaries, provides healthcare services and solutions in India, Uganda, Tanzania, Nigeria, Mauritius, and the United Arab Emirates. It operates through four segments: Hospitals and Medical Centers, Healthcare Consultancy, Distribution and Trade, and Medical Value Travel. The company engages in the operation of multi-specialty tertiary-care hospitals and specialized medical centers under the UMC Hospitals brand name. It also offers healthcare consultancy services, including project report and feasibility study, medical planning and procurement, quality management and accreditation, operations and management, architectural planning and designing, management consultancy, business process restructuring, and project management consultancy; distributes and trades in pharmaceuticals, medical consumables, nutraceuticals, and medical equipment; and provides medical travel facilitation services. The company’s services are used in various therapeu
1. Healthcare Services and Trading in Its Related Products-This segment provides healthcare services, as well as trades in related products. 2. NA-NA 3. NA-NA 4. NA-NA
1. Healthcare Services and Trading in Its Related Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Limited | ₹1,23,712 Cr | 63 | 21.50% | ₹7,615 Cr | +11.6% |
| Max Healthcare Institute Ltd | ₹91,978 Cr | 63.9 | 14.33% | ₹2,569 Cr | -16.6% |
| Manipal Health Enterprises Ltd | ₹89,110 Cr | 88.4 | — | ₹3,399 Cr | — |
| Aster Dm Healthcare Limited (Asterdm) | ₹63,041 Cr | 97.6 | 10.07% | ₹2,829 Cr | +4.3% |
| Fortis Healthcare Ltd. | ₹58,283 Cr | 55.1 | 11.01% | ₹2,735 Cr | -25.1% |
| Global Health Ltd (Medanta) | ₹38,422 Cr | 69.7 | 15.03% | ₹1,469 Cr | +16.2% |
| Narayana Hrudayalaya Limited | ₹37,907 Cr | 46.2 | 19.85% | ₹2,844 Cr | +2.8% |
| Krishna Institute Of Medical Science (KIMS) | ₹29,056 Cr | 120.6 | 9.72% | ₹1,344 Cr | +0.2% |
| Unihealth Hospitals Limited | ₹863 Cr | 33.3 | 30.34% | — | +242.2% |
Listed by market capitalisation. Ratios are shown for context only.
Unihealth Hospitals Limited is trading at ₹549.95, with a market capitalisation of ₹863 Cr.
Unihealth Hospitals Limited operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Facilities > Hospitals and Healthcare Centers).
Unihealth Hospitals Limited has a P/E of 33.3 and a return on equity of 30.34%.
Unihealth Hospitals Limited is listed on the NSE under the symbol UNIHEALTH.
Unihealth Hospitals Limited's share price is up 242.2% over one year and down 23.9% over three months. Its 52-week range is ₹155.00 to ₹820.00.
Promoters held 64.82% of Unihealth Hospitals Limited's shares as of Sept 2026, against 69.14% in Sept 2025 (−4.32 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.